WE'RE DEDICATED TO FINDING ATREATMENT FOR SMA
In collaboration with Astellas, Cytokinetics is developing CK-2127107 (CK-107), a fast skeletal muscle troponin activator (FSTA) as a potential treatment for people living with debilitating diseases and conditions associated with neuromuscular or non-neuromuscular dysfunction, muscular weakness, and/or muscle fatigue.
Like tirasemtiv, CK-107, an investigational drug candidate, is intended to slow the rate of calcium release from the regulatory troponin complex of fast skeletal muscle fibers. CK-107 is a next-generation skeletal muscle compound that may improve muscle function and physical performance in people with SMA, COPD, elderly adults with limited mobility and ALS.
CK-107 has been the subject of five completed Phase 1 clinical trials in healthy volunteers, which evaluated safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics. It is currently the subject of four clinical trials: a Phase 2 trial assessing its effect on multiple measures of muscle function in patients with Type II, Type III, or Type IV SMA, a Phase 2 trial evaluating its effect on physical function and exercise tolerance in patients with COPD, a Phase 2 trial investigating its effect on measures of respiratory function and skeletal muscle function in patients with ALS, and a Phase 1b trial investigating its effect on measures of physical function in elderly adults with limited mobility.